Immunosuppressive therapy in myelodysplastic syndrome
11 Visninger
administrator
07/04/23
Dr Stahl speaks with ecancer at the 2017 ASH annual meeting about the use of immunosuppressive therapy in patients with the myelodysplastic syndromes.
He outlines biomarkers assessed in the hopes of finding predictive factors for patient response, noting that only SF3B1 mutations were validated, negatively affecting response to IST.
Dr Stahl also describes differences in overall survival for patients achieving an objective response.
ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Vis mere
Facebook kommentarer
Ingen kommentarer fundet